Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
- Author:
Soo Yong LEE
1
;
Tae Wook LEE
;
Gyu Tae PARK
;
Jae Ho KIM
;
Hyun-Chae LEE
;
Jung-Hwa HAN
;
Aeseon YOON
;
Dahye YOON
;
Shukmann KIM
;
Soon Myung JUNG
;
Jin Hee CHOI
;
Min Ku CHON
;
Sang Hyun LEE
;
Ki Won HWANG
;
Jeongsu KIM
;
Yong Hyun PARK
;
June Hong KIM
;
Kook Jin CHUN
;
Jin HUR
Author Information
- Publication Type:Original Research
- From:Korean Circulation Journal 2021;51(3):251-262
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background and Objectives:Large clinical studies of sodium/glucose cotransporter 2 (SGLT2) inhibitors have shown a significant beneficial effect on heart failure-associated hospitalization and cardiovascular events. As SGLT2 is known to be absent in heart cells, improved cardiovascular outcomes are thought to be accounted for by the indirect effects of the drug. We sought to confirm whether such benefits were mediated through SGLT2 expressed in the heart using myocardial infarction (MI) model.
Methods:Mice pre-treated with empagliflozin (EMPA), an SGLT2 inhibitor, showed a significantly reduced infarct size compared with the vehicle group three days post-MI.Interestingly, we confirmed SGLT2 localized in the infarct zone. The sequential changes of SGLT2 expression after MI were also evaluated.
Results:One day after MI, SGLT2 transiently appeared in the ischemic areas in the vehicle group and increased until 72 hours. The appearance of SGLT2 was delayed and less in amount compared with the vehicle group. Additionally, there was a significant difference in metabolites, including glucose and amino acids in the 1 H nuclear magnetic resonance analysis between groups.
Conclusions:Our work demonstrates that SGLT2 is transiently expressed in heart tissue early after MI and EMPA may directly operate on SGLT2 to facilitate metabolic substrates shifts.
